Stock Market & Financial Investment News

News Breaks November 12, 2012 07:30 EDT GILD Gilead volatility elevated into positive data from ELECTRON study regimens Gilead overall option implied volatility of 41 is above its 26-week average of 31 according to Track Data, suggesting larger price movement into announcing positive interim data from the ongoing Phase 2 ELECTRON study. News For GILD From The Last 14 Days Check below for free stories on GILD the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 18, 2013 07:28 EDT GILD Wells Faro to host a conference Subscribe for More Information June 17, 2013 16:00 EDT GILD Options Update; June 17, 2013 Subscribe for More Information 06:25 EDT GILD Gilead reports interim Phase 2 data for Idelalisib Gilead announced interim results from a single-arm, open-label Phase 2 study evaluating idelalisib, an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin’s lymphoma that is refractory to rituximab and to alkylating-agent-containing chemotherapy. Previously, this has been a largely unstudied population for which there is significant unmet medical need for effective therapy. In the study, single-agent treatment with idelalisib achieved an overall response rate of 53.6%, with a median duration of response at this interim analysis of 11.9 months. The most common Grade ≥3 adverse event was diarrhea . Grade ≥3 transaminase elevations were reported via central laboratory testing in 13% of patients; Grade ≥3 neutropenia occurred in 26% of patients. Sixteen percent of patients discontinued due to adverse events. June 13, 2013 10:05 EDT GILD On The Fly: Analyst Upgrade Summary Subscribe for More Information 07:33 EDT GILD Gilead upgraded to Buy from Hold at Argus Subscribe for More Information June 10, 2013 07:40 EDT GILD Leerink's biotech analyst holds analyst/industry conference call on ASCO Subscribe for More Information June 7, 2013 17:21 EDT GILD Gilead announces U.S. FDA priority review designation for Sofosbuvir Subscribe for More Information June 6, 2013 09:07 EDT GILD Gilead Sofosbuvir likely to be granted priority review, says RBC Capital Subscribe for More Information 08:27 EDT GILD Bernstein's biotech analysts hold an analyst/industry conference call Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.